MedTrace Logo

Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain

NCT01875848 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-12-21

Study results available
· View outcomes & findings →

Summary

This study compares buprenorphine/naloxone to opioid dose escalation among patients with poorly controlled non-cancer pain on 30-100 mg daily morphine equivalent opioid dose.

Conditions

Interventions

DRUG

buprenorphine/naloxone

partial opioid agonist

DRUG

opioid dose escalation

up to 25% increase in patient's current opioid dose

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • William C Becker, MD · VA Connecticut Healthcare System West Haven Campus, West Haven, CT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01875848 on ClinicalTrials.gov